Syngen BiotechLtd Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Wei Chen
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 19.4yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 11.5yrs |
Recent management updates
Recent updates
Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?
Mar 25
Should Syngen Biotech Co., Ltd. (GTSM:8279) Be Part Of Your Dividend Portfolio?
Feb 25Did You Miss Syngen Biotech's (GTSM:8279) Impressive 104% Share Price Gain?
Feb 04Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?
Jan 14Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly
Dec 16
Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?
Nov 25CEO
Wei Chen
19.4yrs
Tenure
Wei Ren Chen has been Chairman of the Board and President of Syngen Biotech Co., Ltd. since March 15, 1999 and July 1, 2005 respectively. Wei Ren Chen is employed by Taiwan Drug Relief Foundation.Wei Ren...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board and President | 25.8yrs | no data | no data | |
| Finance Manager and Director | 11.5yrs | no data | no data | |
| Director | 11.5yrs | no data | no data | |
| Director | 11.5yrs | no data | no data | |
| Supervisor | 11.5yrs | no data | no data | |
| Supervisor | 11.5yrs | no data | 1.15% NT$ 39.6m | |
| Director | 11.5yrs | no data | no data |
11.5yrs
Average Tenure
Experienced Board: 8279's board of directors are seasoned and experienced ( 11.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 02:50 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Syngen Biotech Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| Hsiu Chi Lin | Masterlink Securities Corp. |